MedTrace Logo

A Study in the Treatment of Osteoarthritis Knee Pain

NCT00790790 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 147

Last updated 2012-04-17

Study results available
· View outcomes & findings →

Summary

To gather data on whether a new drug for osteoarthritis knee pain will be safe and have an effect on pain levels.

Conditions

  • Osteoarthritis Knee Pain

Interventions

DRUG

Placebo

LY545694 placebo BID po for 5 weeks

DRUG

LY545694 49 mg

LY545694 49 mg BID po for 5 weeks.

DRUG

LY545694 105 mg

LY545694 105 mg BID po for 5 weeks.

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States
  • Puerto Rico
  • Romania

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00790790 on ClinicalTrials.gov